Related Experiment Videos

CD34+ stem cells in chronic myeloproliferative disorders

J Thiele1, H M Kvasnicka

  • 1Institute of Pathology, University of Cologne, Germany. j.thiele@uni-koeln.de

Summary

CD34+ stem cell counts in myeloproliferative disorders offer insights into disease progression and treatment response. Higher counts in CML may indicate unfavorable prognosis, while dynamics in IMF and PV relate to hematopoietic capacity.

Related Concept Videos